Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Express Scripts
Mallinckrodt
Moodys
Dow

Last Updated: May 26, 2022

TRIGLIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Triglide, and when can generic versions of Triglide launch?

Triglide is a drug marketed by Skyepharma Ag and is included in one NDA.

The generic ingredient in TRIGLIDE is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

Drug patent expirations by year for TRIGLIDE
Drug Prices for TRIGLIDE

See drug prices for TRIGLIDE

Drug Sales Revenue Trends for TRIGLIDE

See drug sales revenues for TRIGLIDE

Recent Clinical Trials for TRIGLIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Medical University of South CarolinaPhase 4
National Institutes of Health (NIH)N/A
National Heart, Lung, and Blood Institute (NHLBI)N/A

See all TRIGLIDE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for TRIGLIDE

US Patents and Regulatory Information for TRIGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 DISCN No No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 BX RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRIGLIDE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 See Plans and Pricing See Plans and Pricing
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRIGLIDE

See the table below for patents covering TRIGLIDE around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 1322289 PROCEDE DE SECHAGE PAR ATOMISATION DES COMPOSITIONS DE FENOFIBRATE (SPRAY DRYING PROCESS OF COMPOSITIONS CONTAINING FENOFIBRATE) See Plans and Pricing
Australia 2001259099 See Plans and Pricing
Germany 60127457 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Harvard Business School
Johnson and Johnson
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.